Adamantinoma is a rare, low-grade malignant primary bone tumor with a striking predilection for the diaphysis and metaphysis of the tibia (occasionally the fibula, and rarely other long bones), accounting for less than 0.1-0.5% of all primary bone tumors. It is histologically biphasic, combining keratin- and p63-positive epithelial cell nests within an osteofibrous (fibro-osseous) stroma, and is named for its histological resemblance to ameloblastoma ("adamantinoma" of the jaw) despite arising in an unrelated anatomic site and lineage. WHO classification recognizes classic adamantinoma (with tubular, basaloid, spindle-cell, and squamoid growth patterns), the osteofibrous dysplasia-like (OFD-like) form, and a rare dedifferentiated form with high-grade sarcomatous transformation; these are curated here as histopathologic variants of a single entity rather than as subtypes, because the boundaries between them are diagnostically unstable and the relationship between osteofibrous dysplasia, OFD-like adamantinoma, and classic adamantinoma remains a genuinely unsettled histogenetic question (see `discussions`). Despite its low-grade designation, adamantinoma carries a substantial long-term risk of local recurrence (15-31% for classic adamantinoma, 22-43% for the OFD-like form) and pulmonary metastasis (10-27%, essentially confined to classic adamantinoma), with recurrences reported more than 15 years after initial treatment. Wide surgical resection with uncontaminated margins is the most consistently protective factor and the mainstay of treatment, as the tumor is largely resistant to conventional chemotherapy and radiotherapy.
Ask a research question about Adamantinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Adamantinoma:
name: Adamantinoma
creation_date: "2026-08-26T23:27:22Z"
category: Cancer
categories:
- Bone Cancer
- Rare Cancer
- Low-Grade Malignant Neoplasm
synonyms:
- Adamantinoma of long bones
- Adamantinoma of the tibia
description: >-
Adamantinoma is a rare, low-grade malignant primary bone tumor with a
striking predilection for the diaphysis and metaphysis of the tibia
(occasionally the fibula, and rarely other long bones), accounting for
less than 0.1-0.5% of all primary bone tumors. It is histologically
biphasic, combining keratin- and p63-positive epithelial cell nests
within an osteofibrous (fibro-osseous) stroma, and is named for its
histological resemblance to ameloblastoma ("adamantinoma" of the jaw)
despite arising in an unrelated anatomic site and lineage. WHO
classification recognizes classic adamantinoma (with tubular, basaloid,
spindle-cell, and squamoid growth patterns), the osteofibrous
dysplasia-like (OFD-like) form, and a rare dedifferentiated form with
high-grade sarcomatous transformation; these are curated here as
histopathologic variants of a single entity rather than as subtypes,
because the boundaries between them are diagnostically unstable and the
relationship between osteofibrous dysplasia, OFD-like adamantinoma, and
classic adamantinoma remains a genuinely unsettled histogenetic question
(see `discussions`). Despite its low-grade designation, adamantinoma
carries a substantial long-term risk of local recurrence (15-31% for
classic adamantinoma, 22-43% for the OFD-like form) and pulmonary
metastasis (10-27%, essentially confined to classic adamantinoma), with
recurrences reported more than 15 years after initial treatment. Wide
surgical resection with uncontaminated margins is the most consistently
protective factor and the mainstay of treatment, as the tumor is largely
resistant to conventional chemotherapy and radiotherapy.
disease_term:
preferred_term: adamantinoma
term:
id: MONDO:0002422
label: adamantinoma
parents:
- Bone Cancer
prevalence:
- population: United States (SEER Program, ICD-O-3 code 9261/3)
measure_type: CASES_IN_LITERATURE
prevalence_class: ULTRA_RARE
notes: >-
74 patients identified in the SEER registry; median age at diagnosis
20-24 years.
evidence:
- reference: PMID:39555331
reference_title: "Adamantinoma: A SEER-based Epidemiological Analysis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Adamantinoma (AD) is a rare bone cancer accounting for less than 0.1-0.5% of all primary bone tumors."
explanation: >-
SEER-based epidemiological analysis directly quantifying the
population-level rarity of adamantinoma among primary bone tumors.
pathophysiology:
- name: Biphasic Epithelial-Osteofibrous Neoplastic Proliferation
biological_scale: TISSUE
description: >-
Adamantinoma is defined by a neoplastic proliferation of keratin- and
p63-positive epithelial cells, arranged in tubular, basaloid,
spindle-cell, or squamoid patterns, embedded within a fibro-osseous
(osteofibrous) stroma. The epithelial component shows a keratin
subclass immunoreactivity pattern (widespread keratin 14 and 19, with
keratin 5 in the majority of cases) that is independent of histologic
growth pattern and is conserved in local recurrences and metastases,
supporting a common basal epithelial cell-like histogenesis for all
growth patterns. Almost all tumors arise in the tibial diaphysis or
metaphysis.
cell_types:
- preferred_term: basal epithelial-like tumor cell
term:
id: CL:0000646
label: basal cell
- preferred_term: osteofibrous stromal fibroblast
term:
id: CL:0000057
label: fibroblast
locations:
- preferred_term: tibial diaphysis
term:
id: UBERON:0013280
label: diaphysis of tibia
biological_processes:
- preferred_term: aberrant basal epithelial differentiation of tumor cells
modifier: ABNORMAL
term:
id: GO:0030855
label: epithelial cell differentiation
evidence:
- reference: PMID:7694513
reference_title: "Adamantinoma of the long bones: keratin subclass immunoreactivity pattern with reference to its histogenesis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The results revealed the widespread presence of keratins 14 and 19
in all specimens studied; 74% showed immunoreactivity of keratin 5
explanation: >-
Establishes the conserved keratin immunoprofile of the epithelial
component across adamantinoma growth patterns and recurrences.
- reference: PMID:7694513
reference_title: "Adamantinoma of the long bones: keratin subclass immunoreactivity pattern with reference to its histogenesis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our results suggest a basal epithelial cell-like differentiation of adamantinomas."
explanation: Directly supports the basal epithelial-like histogenesis claim.
downstream:
- target: Local Cortical Bone Destruction and Structural Compromise
description: >-
Intraosseous tumor growth destroys and remodels adjacent cortical
bone in the tibial diaphysis.
- name: Recurrent Chromosomal Copy-Number Gains Without an Established Driver
biological_scale: MOLECULAR
mechanism_confidence: PROVISIONAL
description: >-
Cytogenetic and, more recently, genomic studies of classic adamantinoma
recurrently identify extra copies of chromosomes 7, 8, 12, 19, and 21
(and, in a targeted sequencing/SNP-array series, chromosomes 7, 8, 10,
12, and/or 19), sometimes accompanied by isolated structural events
(e.g., a chromosome 12q tandem duplication, an FGFR1 rearrangement, or
an NRAS p.G12D variant in single cases). No single recurrent driver
gene, mutation, or fusion has been established across cases: this
genomic profile is what most clearly distinguishes true adamantinoma
from its principal molecular mimic, "adamantinoma-like Ewing sarcoma,"
which instead carries the canonical EWSR1::FLI1/ERG t(11;22) or t(21;22)
translocations that are consistently absent from true adamantinoma.
Osteofibrous dysplasia-like adamantinoma is genomically heterogeneous
and, in a small paired series, could show either no detectable
variants or the same chromosome 7/8/19 gain pattern as classic
adamantinoma, so genomic profiling has been proposed as an aid to (but
not yet a settled arbiter of) distinguishing these entities.
evidence:
- reference: PMID:11227067
reference_title: "Extra copies of chromosomes 7, 8, 12, 19, and 21 are recurrent in adamantinoma"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cytogenetic or molecular cytogenetic analysis of four adamantinomas,
and a review of eleven cases in the literature reveals extra copies
of chromosomes 7, 8, 12, 19, and 21 as recurrent in this neoplasm.
explanation: Establishes the recurrent whole-chromosome copy-number gain pattern.
- reference: PMID:9242211
reference_title: "Cytogenetic analysis of adamantinoma of long bones: further indications for a common histogenesis with osteofibrous dysplasia"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Two of them revealed trisomies 7, 8, 12, and 19, combined with a
balanced translocation, t(10;12), with centromere breakpoints in one
tumor.
explanation: >-
Independent cytogenetic series confirming the recurrent trisomy
pattern and demonstrating additional structural heterogeneity
between cases (no single lesion is shared by all tumors).
- reference: PMID:42379271
reference_title: "Genomic Characterization of Classic Adamantinoma, Osteofibrous Dysplasia, and Osteofibrous Dysplasia-like Adamantinoma"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The 3 classic adamantinomas harbored multiple copy number gains
involving chromosome 7, 8, 10, 12, and/or 19. Focal deletion of
chromosome 17, intergenic rearrangement involving FGFR1, and NRAS
p.G12D were each present in 1 classic adamantinoma.
explanation: >-
Contemporary NGS/SNP-array/Hi-C study confirming the copy-number
gain pattern and showing that isolated structural/point variants
differ from tumor to tumor rather than converging on one driver.
- reference: PMID:11592101
reference_title: "Adamantinoma-like Ewing's sarcoma and Ewing's-like adamantinoma. The t(11; 22), t(21; 22) status"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This study investigated the putative presence of t(11; 22) and
t(21; 22) in 14 cases of adamantinoma by RT-PCR. These translocations
were not found in any of these cases.
explanation: >-
Shows true adamantinoma lacks the EWSR1 translocations that define
its principal molecular mimic, adamantinoma-like Ewing sarcoma,
supporting genomic distinctness despite morphologic overlap.
- name: Local Cortical Bone Destruction and Structural Compromise
biological_scale: TISSUE
description: >-
Progressive intracortical and intramedullary tumor growth within the
tibial diaphysis destroys and thins cortical bone, producing anterior
tibial bowing, a palpable mass, bone pain, and, in advanced or
long-standing disease, structural weakening predisposing to pathologic
fracture.
locations:
- preferred_term: tibial diaphysis
term:
id: UBERON:0013280
label: diaphysis of tibia
downstream:
- target: Tibial Bowing
description: Cortical destruction and remodeling produce progressive anterior bowing of the tibia.
- target: Bone Pain
description: Local tumor growth and cortical destruction cause chronic bone pain.
- target: Localized Extremity Mass
description: Tumor expansion produces a palpable soft-tissue swelling over the involved bone.
- target: Pathologic Fracture
description: Cortical thinning from tumor growth predisposes to fracture through the involved bone.
evidence:
- reference: PMID:30844202
reference_title: "Adamantinoma"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Adamantinomas are rare, low-grade malignant bone tumors of uncertain
histogenesis that predominately affect the diaphyses and metaphyses
of the tibia.
explanation: Establishes the anatomic site of the destructive tumor process.
- name: Local Recurrence After Incomplete Surgical Resection
biological_scale: TISSUE
description: >-
Local recurrence is common and can occur late (documented beyond 15
years post-treatment). Across a synthesized literature base, local
recurrence rates range from 15-31% for classic adamantinoma and
22-43% for the OFD-like variant. Wide resection with uncontaminated
margins is the most consistently protective surgical variable
identified across the case-series literature; intralesional or
marginal margins predispose to recurrence.
downstream:
- target: Hematogenous and Lymphatic Metastasis
description: >-
Recurrent and spindle/basaloid-pattern classic adamantinoma is
disproportionately associated with subsequent metastatic disease.
evidence:
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Local recurrence rates for classic adamantinoma (AD) range from 15%
to 31%, with metastatic rates from 10% to 27%, predominantly to the
lung.
explanation: Quantifies the recurrence and metastasis rates from a synthesis of the case-series literature.
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Wide resection with uncontaminated margins is the most consistently
protective surgical variable (hazard ratio 0.164; p < 0.001).
explanation: Quantifies the protective effect of margin status on outcome.
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Late recurrences beyond 15 years are documented in multiple series, supporting prolonged surveillance."
explanation: Documents the long natural history requiring lifelong surveillance.
- reference: PMID:41653544
reference_title: "Clinicopathological analysis of osteofibrous dysplasia and adamantinoma: A single institution experience"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The most commonly associated patterns with recurrences and
metastasis in a classic adamantinoma were spindle and basaloid.
explanation: Links specific classic-adamantinoma growth patterns to a higher risk of recurrence and metastasis.
- name: Hematogenous and Lymphatic Metastasis
biological_scale: ORGANISM
description: >-
Classic adamantinoma metastasizes predominantly to the lungs, in an
estimated 10-27% of cases, but metastatic spread is not confined to
the lung: it is also reported to regional lymph nodes (including a
case with inguinal nodal recurrence and no pulmonary disease at all)
and, less commonly, to abdominal/pelvic sites, liver, brain, and
skeleton. In contrast, the OFD-like variant, despite a locally
aggressive recurrence rate, shows no metastases in series that report
it separately, indicating a biologically distinct clinical behavior
from classic adamantinoma despite their morphologic overlap.
locations:
- preferred_term: lung
term:
id: UBERON:0002048
label: lung
- preferred_term: lymph node
term:
id: UBERON:0000029
label: lymph node
downstream:
- target: Pulmonary Metastasis
description: Hematogenous spread establishes secondary tumor deposits in the lung.
- target: Nodal Metastasis
description: Lymphatic spread establishes secondary tumor deposits in regional lymph nodes.
evidence:
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The osteofibrous dysplasia-like subtype (OFD-AD) showed no
metastases in any series that reports this subtype separately but
carries a locally aggressive recurrence rate of 22-43%.
explanation: >-
Directly supports the biological distinction between classic
adamantinoma metastatic potential and the OFD-like variant's purely
local aggressiveness.
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Because metastatic spread is not confined to the lung, chest CT
alone may be insufficient for surveillance in selected high-risk
patients, in whom staging beyond the chest should be considered
explanation: >-
Directly supports that metastatic spread extends beyond the lung
alone, motivating the broader nodal/abdominal-pelvic framing of this
node rather than a pulmonary-only model.
- reference: PMID:41653544
reference_title: "Clinicopathological analysis of osteofibrous dysplasia and adamantinoma: A single institution experience"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Five out of 28 (17.9%) patients with an adamantinoma developed recurrences and 5 (17.9) developed metastases."
explanation: Independent single-institution series quantifying metastatic frequency among classic adamantinomas.
- reference: PMID:39555331
reference_title: "Adamantinoma: A SEER-based Epidemiological Analysis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
metastasis occurs at rates as high as 18–32% primarily to lymph
nodes or lungs
explanation: >-
Directly establishes lymph nodes, alongside lungs, as a primary
metastatic site for adamantinoma.
- reference: PMID:38486378
reference_title: "Rare Case of Recurrent Adamantinoma of the Tibia: Limited Efficacy of Pazopanib as a Standalone Treatment"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a positive emission tomography scan revealed mildly increased
tracer uptake near the area of the previous lesion and in the right
inguinal lymph node. Biopsies of the lesion and inguinal lymph node
confirmed recurrence of the adamantinoma. Due to abdominal and
pelvic metastasis
explanation: >-
Case-level evidence of inguinal lymph node and abdominal/pelvic
metastatic recurrence with no lung involvement reported, directly
motivating a nodal (not pulmonary-only) metastasis model.
- name: Sarcomatoid Dedifferentiation with Loss of Epithelial Phenotype
biological_scale: CELLULAR
mechanism_confidence: PROVISIONAL
description: >-
Rarely, classic adamantinoma undergoes high-grade sarcomatoid
transformation, with progressive loss of pankeratin and other
epithelial marker expression in the transformed component (a
"revertant mesenchymal phenotype"). This dedifferentiated form behaves
more aggressively; the evidence base for its mechanism is limited to a
small number of case reports.
evidence:
- reference: PMID:20717000
reference_title: "Dedifferentiated classic adamantinoma of the tibia: a report of a case with eventual complete revertant mesenchymal phenotype"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
On the en bloc resection specimen, areas of classic adamantinoma
were found but most of the tumor corresponded to a high-grade
neoplasm with 2 histologic patterns: one made up by epithelial nests
with a basaloid arrangement and positive for pankeratins and
so-called glandular keratins, and a second sarcomatoid component,
negative for these epithelial markers.
explanation: Direct description of a dedifferentiated adamantinoma with sarcomatoid loss of the epithelial immunophenotype.
downstream:
- target: Hematogenous and Lymphatic Metastasis
description: >-
Dedifferentiated/sarcomatoid transformation is associated with more
aggressive, higher-risk clinical behavior including relapse and
metastasis in reported cases.
phenotypes:
- name: Tibial Bowing
category: Skeletal
description: >-
Progressive anterior angular deformity (bowing) of the tibia, a
recognized presenting or associated finding across the OFD/adamantinoma
spectrum, particularly well documented for the OFD and OFD-like end of
that spectrum and in younger patients.
phenotype_term:
preferred_term: Tibial bowing
term:
id: HP:0002982
label: Tibial bowing
evidence:
- reference: PMID:35094574
reference_title: "Osteofibrous dysplasia of the tibia : the importance of deformity in surveillance"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
41 lesions (40.6%) presented with radiological deformity (> 10°):
apex anterior in 97.6%.
explanation: >-
Directly quantifies anterior angular tibial deformity (bowing) in a
101-lesion tibial OFD case series, the benign end of the
OFD/adamantinoma spectrum this phenotype describes.
- reference: PMID:38539216
reference_title: "Osteofibrous dysplasia: a narrative review"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
OFD can present with asymptomatic, mass, pain, swelling, deformity
(anterior bowing of the tibia), and even pathological fracture
explanation: >-
Independent narrative review confirming anterior tibial bowing
(deformity) as a recognized clinical presentation across the
OFD/adamantinoma spectrum.
- name: Bone Pain
category: Musculoskeletal
description: >-
Local pain over the involved tibial segment, a common presenting
complaint, typically accompanying a palpable mass.
phenotype_term:
preferred_term: Bone pain
term:
id: HP:0002653
label: Bone pain
evidence:
- reference: PMID:39555331
reference_title: "Adamantinoma: A SEER-based Epidemiological Analysis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "patients typically present with a painful, swollen mass which can be palpated."
explanation: Direct support for pain as a common presenting feature.
- name: Localized Extremity Mass
category: Musculoskeletal
description: >-
A palpable mass or swelling overlying the involved bone, typically
accompanying bone pain rather than presenting painlessly.
phenotype_term:
preferred_term: Localized soft-tissue mass of the leg
term:
id: HP:6000840
label: Localized soft-tissue swelling on extremity
evidence:
- reference: PMID:39555331
reference_title: "Adamantinoma: A SEER-based Epidemiological Analysis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "patients typically present with a painful, swollen mass which can be palpated."
explanation: Direct support for a palpable mass as a common presenting feature.
- name: Pathologic Fracture
category: Musculoskeletal
description: >-
Fracture through bone weakened by tumor-related cortical destruction;
reported at presentation in 10-21% of cases across series, and an
independent predictor of local recurrence.
phenotype_term:
preferred_term: Pathologic fracture
term:
id: HP:0002756
label: Pathologic fracture
evidence:
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pathological fracture at presentation was recorded in 10% to 21%
across series
explanation: Quantifies pathologic fracture frequency at presentation.
- name: Bone Neoplasm
category: Neoplastic
description: >-
A primary bone neoplasm, almost always centered in the tibial
diaphysis or metaphysis.
phenotype_term:
preferred_term: Adamantinoma of bone
term:
id: HP:0010622
label: Neoplasm of the skeletal system
- name: Osteolytic Bone Lesion
category: Skeletal
description: >-
Radiographically, the tumor characteristically appears as a lytic
(osteolytic) lesion with sclerotic margins and overlapping
radiolucency, producing the classic "soap-bubble" appearance (see
`diagnosis#Plain Radiography (Soap-Bubble Osteolytic Lesion)`).
phenotype_term:
preferred_term: Osteolytic soap-bubble lesion of the tibia
term:
id: HP:0002797
label: Osteolysis
evidence:
- reference: PMID:34697136
reference_title: "Adamantinoma: An Updated Review"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In X-ray, it is usually seen as an eccentric and sometimes central,
lobular, lytic lesion with sclerotic margins of overlapping
radiolucency, and a characteristic 'soap-bubble' appearance.
explanation: Direct description of the characteristic osteolytic radiographic appearance.
- name: Pulmonary Metastasis
category: Neoplastic
description: >-
Hematogenous metastasis to the lung, reported in approximately 10-27%
of classic adamantinoma cases; not reported for the OFD-like variant
in series reporting it separately.
phenotype_term:
preferred_term: Pulmonary metastasis of adamantinoma
term:
id: HP:0100526
label: Neoplasm of the lung
evidence:
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Local recurrence rates for classic adamantinoma (AD) range from 15%
to 31%, with metastatic rates from 10% to 27%, predominantly to the
lung.
explanation: Direct support for lung as the predominant metastatic site.
- name: Nodal Metastasis
category: Neoplastic
description: >-
Metastasis to regional lymph nodes, reported as a primary metastatic
site alongside the lungs; a documented case shows nodal (inguinal)
recurrence with abdominal/pelvic spread and no pulmonary involvement,
so this is not simply a rarer variant of pulmonary spread.
phenotype_term:
preferred_term: Lymph node metastasis of adamantinoma
term:
id: HP:0002733
label: Abnormal lymph node morphology
evidence:
- reference: PMID:39555331
reference_title: "Adamantinoma: A SEER-based Epidemiological Analysis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
metastasis occurs at rates as high as 18–32% primarily to lymph
nodes or lungs
explanation: Directly establishes lymph nodes as a primary metastatic site.
- reference: PMID:38486378
reference_title: "Rare Case of Recurrent Adamantinoma of the Tibia: Limited Efficacy of Pazopanib as a Standalone Treatment"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a positive emission tomography scan revealed mildly increased
tracer uptake near the area of the previous lesion and in the right
inguinal lymph node. Biopsies of the lesion and inguinal lymph node
confirmed recurrence of the adamantinoma
explanation: Case-level confirmation of inguinal lymph node metastatic recurrence.
histopathology:
- name: Keratin/p63-Positive Epithelial Immunoprofile
diagnostic: true
description: >-
The neoplastic epithelial nests express pankeratin (AE1/AE3) in
approximately 95% of cases, with p40 and p63 also positive in the
large majority of cases; this keratin/p63 epithelial immunoprofile
within an otherwise osteofibrous bone lesion is the diagnostic anchor
that establishes an epithelial (rather than purely mesenchymal or
fibro-osseous) neoplasm.
finding_term:
preferred_term: Cytokeratin and p63 co-expression in epithelial tumor nests
term:
id: NCIT:C81765
label: Cytokeratin-Positive Neoplastic Cells Present
frequency: VERY_FREQUENT
evidence:
- reference: PMID:41653544
reference_title: "Clinicopathological analysis of osteofibrous dysplasia and adamantinoma: A single institution experience"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pan keratin (AE1/AE3) was positive in 18/19 (94.7%) OFDs and 19/20
(95%) adamantinomas. P40 (5/5, 100%) and p63 (6/8, 75%) were useful
in the diagnosis of adamantinoma.
explanation: Direct quantification of pankeratin/p40/p63 positivity rates.
- reference: PMID:21674157
reference_title: "p63 expression in adamantinoma"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The epithelial component in adamantinoma was found to stain for p63."
explanation: Establishes p63 as a marker of the epithelial tumor component.
- name: Tubular/Basaloid/Spindle-Cell/Squamoid Growth Patterns (Classic Adamantinoma)
diagnostic: true
description: >-
Classic adamantinoma displays a spectrum of architectural growth
patterns — tubular, basaloid, spindle-cell, and squamoid — within the
same underlying epithelial-osteofibrous biphasic lesion. The keratin
immunoreactivity pattern is conserved across all of these patterns,
indicating a shared histogenesis; spindle and basaloid patterns are
disproportionately associated with recurrence and metastasis.
finding_term:
preferred_term: Tubular growth pattern
term:
id: NCIT:C35925
label: Tubular Pattern
evidence:
- reference: PMID:7694513
reference_title: "Adamantinoma of the long bones: keratin subclass immunoreactivity pattern with reference to its histogenesis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This keratin immunoreactivity pattern was independent of histologic
subtype, despite marked variety in differentiation pattern,
suggesting a common histogenesis for all subtypes of adamantinoma.
explanation: >-
Directly supports that the growth-pattern variants share a common
histogenesis rather than being distinct entities.
- reference: PMID:41653544
reference_title: "Clinicopathological analysis of osteofibrous dysplasia and adamantinoma: A single institution experience"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The most commonly associated patterns with recurrences and
metastasis in a classic adamantinoma were spindle and basaloid.
explanation: Links specific growth patterns to prognostic behavior.
- name: Osteofibrous Dysplasia-Like Pattern
diagnostic: false
description: >-
A fibro-osseous pattern resembling osteofibrous dysplasia, with only
scattered or focal keratin/p40-positive epithelial cell clusters
(sometimes detectable only by immunostain, not on light microscopy).
Distinguishing an OFD-like adamantinoma from osteofibrous dysplasia
proper, and from classic adamantinoma, is a recognized source of
interobserver diagnostic disagreement (see `discussions`).
finding_term:
preferred_term: Osteofibrous dysplasia-like growth pattern
evidence:
- reference: PMID:42379271
reference_title: "Genomic Characterization of Classic Adamantinoma, Osteofibrous Dysplasia, and Osteofibrous Dysplasia-like Adamantinoma"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
one case with tumor clusters visible only on cytokeratin immunostain
harbored no variants, whereas another case with tumor clusters
visible on light microscopy and cytokeratin/p40 immunostains showed
gains of chromosome 7, 8, 19, and 20
explanation: >-
Documents the diagnostically ambiguous, immunostain-dependent nature
of the OFD-like epithelial component.
- reference: PMID:41653544
reference_title: "Clinicopathological analysis of osteofibrous dysplasia and adamantinoma: A single institution experience"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
After a review, the diagnosis was modified in 12/58 (20.7%) tumors;
with 4 OFDs revised to FDs; 2 FDs to OFDs; 2 intra-osseous SSs to
classic adamantinomas; 3 OFD-like adamantinomas to classic
adamantinomas, and a single de-differentiated adamantinoma to
classic adamantinoma.
explanation: >-
Quantifies the substantial rate of diagnostic revision among OFD,
OFD-like adamantinoma, and classic adamantinoma on expert review,
supporting that these categories are diagnostically unstable rather
than sharply demarcated entities.
- name: Sarcomatoid Dedifferentiation
diagnostic: false
description: >-
A rare high-grade component with loss of epithelial (keratin) marker
expression arising within or after classic adamantinoma, sometimes
with a completely "revertant" mesenchymal/sarcomatoid phenotype on
recurrence.
finding_term:
preferred_term: Sarcomatoid dedifferentiation
term:
id: NCIT:C158781
label: Dedifferentiated Lesion
frequency: VERY_RARE
evidence:
- reference: PMID:20717000
reference_title: "Dedifferentiated classic adamantinoma of the tibia: a report of a case with eventual complete revertant mesenchymal phenotype"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Three cases of adamantinomas with sarcomatoid transformation of the
epithelial component have been described but the tumours still
preserved an epithelial immunophenotype.
explanation: Establishes the rarity and prior documentation of dedifferentiation in adamantinoma.
diagnosis:
- name: Plain Radiography (Soap-Bubble Osteolytic Lesion)
description: >-
Initial imaging is plain radiography, which characteristically shows
an eccentric, lobular, lytic lesion with sclerotic margins of
overlapping radiolucency in the tibial diaphysis -- the classic
"soap-bubble" appearance -- though the radiologic impression does not
reliably predict the underlying histologic diagnosis (see the
centrally-sampled-biopsy caveat below).
diagnosis_term:
preferred_term: plain radiography of the affected bone
term:
id: NCIT:C38101
label: X-Ray Imaging
evidence:
- reference: PMID:34697136
reference_title: "Adamantinoma: An Updated Review"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In X-ray, it is usually seen as an eccentric and sometimes central,
lobular, lytic lesion with sclerotic margins of overlapping
radiolucency, and a characteristic 'soap-bubble' appearance.
explanation: Direct description of the characteristic radiographic appearance.
- name: Whole-Bone MRI for Multifocality and Skip Lesions
description: >-
MRI of the entire involved bone is used both for differential
diagnosis and to detect multifocal disease -- reported in
approximately 24% of cases -- including a singular lobulated focus or
several small nodules within multiple foci that may not be apparent on
plain radiographs alone.
diagnosis_term:
preferred_term: magnetic resonance imaging of the affected bone
term:
id: NCIT:C16809
label: Magnetic Resonance Imaging
evidence:
- reference: PMID:38486378
reference_title: "Rare Case of Recurrent Adamantinoma of the Tibia: Limited Efficacy of Pazopanib as a Standalone Treatment"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
On magnetic resonance imaging (MRI), 2 morphological patterns have
been described: a singular lobulated focus or several small nodules
within multiple foci.
explanation: Directly describes the multifocal/skip-lesion MRI patterns relevant to whole-bone imaging.
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Multifocality occurs in approximately 24% of cases"
explanation: Quantifies the frequency of multifocal disease that whole-bone MRI is intended to detect.
- reference: PMID:34697136
reference_title: "Adamantinoma: An Updated Review"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Magnetic resonance imaging seems to be the most appropriate
examination for differential diagnosis between adamantinoma and
other skeletal tumors.
explanation: Establishes MRI as the preferred differential-diagnosis imaging modality.
- name: Chest CT for Metastatic Staging
description: >-
Chest CT is used for pulmonary metastatic staging given the tumor's
predilection for hematogenous lung spread, but chest CT alone can be
insufficient in high-risk patients because metastatic spread is not
confined to the lung (see `phenotypes#Nodal Metastasis`); staging
beyond the chest should be considered in selected high-risk cases, and
the optimal imaging modality, extent, and frequency of surveillance
remain undefined.
diagnosis_term:
preferred_term: computed tomography of the chest
term:
id: NCIT:C17204
label: Computed Tomography
evidence:
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Because metastatic spread is not confined to the lung, chest CT
alone may be insufficient for surveillance in selected high-risk
patients, in whom staging beyond the chest should be considered
explanation: Directly supports both the chest-CT staging role and its limitation given non-pulmonary metastatic sites.
- name: Centrally-Sampled Biopsy with Immunohistochemistry
description: >-
Because the diagnostic epithelial component can be sparse and
patchy -- especially in OFD-like adamantinoma, where it may be
detectable only by immunostain and not on light microscopy (see
`histopathology#Osteofibrous Dysplasia-Like Pattern`) -- adequate,
ideally centrally-sampled biopsy with immunohistochemistry (pankeratin,
p40, p63) is needed to avoid false-negative or misclassified
diagnoses; radiologic-histologic concordance is imperfect even among
experienced centers.
diagnosis_term:
preferred_term: image-guided biopsy with immunohistochemistry
term:
id: NCIT:C15189
label: Biopsy Procedure
evidence:
- reference: PMID:18279517
reference_title: "Adamantinoma: a clinicopathological review and update"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
To assure the histological diagnosis, pathologists should employ
immunohistochemistry for demonstrating the sometimes sparse
epithelial cell nests when the radiological features are suggestive
of adamantinoma.
explanation: Directly states the sampling/immunohistochemistry caveat for the sparse epithelial component.
- reference: PMID:41653544
reference_title: "Clinicopathological analysis of osteofibrous dysplasia and adamantinoma: A single institution experience"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The radiological impression concurred with the histopathological diagnosis in 40% of OFDs and 60% of adamantinomas."
explanation: Quantifies imperfect radiologic-histologic concordance, motivating reliance on adequately sampled biopsy.
treatments:
- name: Wide En Bloc Surgical Resection
description: >-
Complete surgical excision with uncontaminated (wide) margins is the
standard, and most consistently effective, treatment for adamantinoma.
Conventional chemotherapy and radiotherapy have not been shown to be
reliably effective, so margin-negative surgery is the primary
curative-intent modality; reconstruction (e.g., with a vascularized
fibular graft) is frequently required for the resulting tibial defect.
treatment_term:
preferred_term: en bloc surgical resection
term:
id: NCIT:C139567
label: En Bloc Resection
evidence:
- reference: PMID:42496518
reference_title: "Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Wide resection with uncontaminated margins is the most consistently
protective surgical variable (hazard ratio 0.164; p < 0.001).
explanation: Quantifies the protective effect of wide-margin resection on recurrence risk.
- name: Limb-Sparing Reconstruction
description: >-
Following wide resection of the tibial defect, limb-sparing
reconstructive techniques (including vascularized or non-vascularized
fibular grafts) are used to preserve limb function and avoid
amputation where feasible.
treatment_term:
preferred_term: limb salvage procedure
term:
id: NCIT:C16042
label: Limb Salvage Procedure
- name: Pazopanib (Limited Efficacy in Recurrent/Metastatic Disease)
description: >-
The multi-target tyrosine kinase inhibitor pazopanib has been used in
recurrent/metastatic adamantinoma when surgery alone is no longer
curative, but case-level experience to date indicates limited
standalone efficacy; adamantinoma has no consensus systemic-therapy
guideline.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: pazopanib
term:
id: CHEBI:71219
label: pazopanib
evidence:
- reference: PMID:38486378
reference_title: "Rare Case of Recurrent Adamantinoma of the Tibia: Limited Efficacy of Pazopanib as a Standalone Treatment"
supports: REFUTE
evidence_source: HUMAN_CLINICAL
snippet: "This report showed that pazopanib as standalone treatment does not appear to have promising role on patient outcomes."
explanation: >-
Case report directly reporting limited efficacy of pazopanib
monotherapy for recurrent/metastatic adamantinoma.
notes: >-
A separate case report describes a sustained response to the PARP
inhibitor olaparib in a metastatic adamantinoma harboring a somatic
XRCC2 frameshift mutation (PMID:41370129), illustrating an emerging,
genomically-guided precision-oncology approach for individual
metastatic cases; this is not yet an established or guideline-based
treatment and is not modeled as a separate targeted-therapy entry
given the single-case evidence base.
differential_diagnoses:
- name: Ameloblastoma
description: >-
Ameloblastoma is a locally aggressive odontogenic epithelial tumor of
the jaw (mandible/maxilla) that shares keratin-positive epithelial
histology with adamantinoma of long bone, and historically gave
adamantinoma its name, but the two are anatomically, embryologically,
and clinically distinct entities: ameloblastoma arises from odontogenic
epithelium in the jaw, whereas adamantinoma is a primary bone tumor
with a striking predilection for the tibial diaphysis and no
odontogenic relationship. This entry (MONDO:0002422) is NOT
ameloblastoma (MONDO:0017795).
disease_term:
preferred_term: ameloblastoma
term:
id: MONDO:0017795
label: ameloblastoma
distinguishing_features:
- Arises in the jaw (mandible/maxilla) from odontogenic epithelium, not in long bones
- No predilection for the tibial diaphysis
- Distinct molecular drivers (e.g., BRAF V600E, SMO) not reported as recurrent in true adamantinoma
evidence:
- reference: PMID:30844202
reference_title: "Adamantinoma"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The tumor is called adamantinoma due to its histological similarity
to ameloblastoma, often found in the mandible.
explanation: >-
States the historical basis for the name shared with ameloblastoma
while identifying the mandible as the site specific to ameloblastoma.
- name: Adamantinomatous Craniopharyngioma
description: >-
Adamantinomatous craniopharyngioma is a WHO grade 1 epithelial
neoplasm of the sellar/parasellar region arising from Rathke pouch
epithelial remnants, driven by somatic CTNNB1 mutations. It shares
only a descriptive histological label ("adamantinomatous," for its
resemblance to ameloblastoma/adamantinoma-type epithelium) with the
bone tumor curated in this entry; it is a completely separate
disease, already curated in dismech as `Craniopharyngioma.yaml`, and
is not a form of, subtype of, or related to skeletal adamantinoma
(MONDO:0002422).
disease_term:
preferred_term: craniopharyngioma
term:
id: MONDO:0018907
label: craniopharyngioma
distinguishing_features:
- Arises in the sellar/suprasellar region of the central nervous system, not in bone
- Driven by somatic CTNNB1/Wnt pathway activation, not by the chromosomal copy-number gains seen in skeletal adamantinoma
- Presents with visual, endocrine, and hypothalamic symptoms rather than a limb mass or bone pain
notes: >-
Named entity confusion risk: "adamantinoma" and "adamantinomatous
craniopharyngioma" share only the descriptive adjective, not disease
identity; deep-research and literature-search tools can conflate them.
- name: Adamantinoma-like Ewing Sarcoma
description: >-
A member of the Ewing sarcoma family of tumors that shows aberrant
epithelial (cytokeratin) expression and, in some cases, an
architectural resemblance to adamantinoma, but is genetically defined
by the canonical Ewing sarcoma EWSR1::FLI1 t(11;22) or EWSR1::ERG
t(21;22) translocation. These translocations are consistently absent
in true adamantinoma, despite the misleading shared name.
distinguishing_features:
- Carries the EWSR1::FLI1 t(11;22) or EWSR1::ERG t(21;22) translocation, absent in true adamantinoma
- Not restricted to the tibial diaphysis in the same site-specific pattern as adamantinoma
- Aggressive small round blue cell histology rather than the biphasic epithelial-osteofibrous pattern of adamantinoma
evidence:
- reference: PMID:11592101
reference_title: "Adamantinoma-like Ewing's sarcoma and Ewing's-like adamantinoma. The t(11; 22), t(21; 22) status"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This study investigated the putative presence of t(11; 22) and
t(21; 22) in 14 cases of adamantinoma by RT-PCR. These translocations
were not found in any of these cases. The results support the view
that these tumours are genetically and clinically distinct, but may
eventually show overlapping morphological and immunohistochemical
features.
explanation: >-
Directly establishes the genetic distinction between true
adamantinoma and adamantinoma-like Ewing sarcoma despite
morphologic overlap.
- name: Osteofibrous Dysplasia
description: >-
A benign, self-limited fibro-osseous lesion of the tibial diaphysis in
children, radiologically and histologically similar to OFD-like
adamantinoma; distinguishing the two (and determining whether OFD can
itself progress to adamantinoma) is an open diagnostic and
histogenetic question (see `discussions`).
disease_term:
preferred_term: osteofibrous dysplasia
term:
id: MONDO:0011806
label: osteofibrous dysplasia
distinguishing_features:
- Benign lesion, historically not considered to metastasize
- Typically younger age at presentation (median 10 years vs 25 years for adamantinoma in one series)
- Absent or only very focal/rare p63-positive epithelial cells on immunostain
evidence:
- reference: PMID:41653544
reference_title: "Clinicopathological analysis of osteofibrous dysplasia and adamantinoma: A single institution experience"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The median age for OFD (10 years) was lower than that of adamantinoma (25 years)."
explanation: Quantifies the age-distribution distinction used to help separate the two entities clinically.
discussions:
- discussion_id: adam_ofd_progression_sequence
prompt: >-
Does osteofibrous dysplasia progress through an OFD-like adamantinoma
intermediate to classic adamantinoma along a single histogenetic
continuum, or are these three diagnostically overlapping but
biologically separate entities?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Biphasic Epithelial-Osteofibrous Neoplastic Proliferation
- pathophysiology#Recurrent Chromosomal Copy-Number Gains Without an Established Driver
- histopathology#Osteofibrous Dysplasia-Like Pattern
- differential_diagnoses#Osteofibrous Dysplasia
rationale: >-
Shared cytogenetic findings (trisomies 7, 8, and 12 reported in both
OFD and adamantinoma) and shared, if focal, p63/keratin epithelial
positivity in OFD have long been read as evidence of a common
histogenesis and a possible progression sequence from OFD through
OFD-like adamantinoma to classic adamantinoma. However, a contemporary
genomic comparison found classic adamantinomas carry multiple
chromosome/arm-level copy-number gains that OFDs largely lack, arguing
the two may be genetically distinct rather than points on one
continuum; and the largest recent single-institution clinicopathologic
series observed a morphological continuum among the three diagnoses
but did not observe any OFD progressing to adamantinoma during
prospective follow-up (median 51 months, range 4-98 months). Both the
"shared histogenesis/progression" and "distinct entities" readings
remain live in the literature, and no study to date has followed a
cohort of confirmed OFD cases long enough, with sufficiently
consistent molecular workup, to settle the question. This bears
directly on clinical management: if OFD can progress to a malignant
tumor, that argues for closer surveillance of pediatric OFD than is
currently standard.
proposed_experiments:
- experiment_id: exp_adam_ofd_longitudinal_molecular_cohort
name: Prospective longitudinal molecular cohort of OFD, OFD-like adamantinoma, and classic adamantinoma
description: >-
Assemble a multi-institutional cohort of histologically confirmed
OFD cases with long-term (>15 year) clinical and radiographic
follow-up, paired with serial genomic profiling (copy-number/SNP
array or targeted sequencing) of the lesion at diagnosis and at any
subsequent biopsy or recurrence, to determine whether any lesion
acquires the classic-adamantinoma copy-number gain pattern over time
and whether that acquisition precedes clinical/histologic
progression.
evidence:
- reference: PMID:9242211
reference_title: "Cytogenetic analysis of adamantinoma of long bones: further indications for a common histogenesis with osteofibrous dysplasia"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The trisomies 7, 8, and 12 also were described in OFD, which
suggests a common histogenesis of OFD and adamantinoma.
explanation: Represents the "shared histogenesis/progression" position in the literature.
- reference: PMID:12679847
reference_title: "Adamantinoma, osteofibrous dysplasia and differentiated adamantinoma"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Cytokeratin subset immunohistochemical stains and cytogenetic
studies performed in recent years suggest a common histogenesis for
these three entities.
explanation: >-
Independent review reinforcing the "shared histogenesis/progression"
position across OFD, OFD-like adamantinoma, and classic
adamantinoma.
- reference: PMID:42379271
reference_title: "Genomic Characterization of Classic Adamantinoma, Osteofibrous Dysplasia, and Osteofibrous Dysplasia-like Adamantinoma"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In conclusion, classic adamantinomas and OFD might be genetically
distinct. Classic adamantinomas harbored multiple alterations,
including chromosome/arm-level copy number gains, the detection of
which could aid their distinction from OFDs.
explanation: >-
Represents the more recent, genomically-based "distinct entities"
position, in tension with the earlier common-histogenesis reading.
- reference: PMID:41653544
reference_title: "Clinicopathological analysis of osteofibrous dysplasia and adamantinoma: A single institution experience"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Although there is a morphological continuum between OFD and
adamantinoma, we did not observe a disease progression during the
limited follow-up.
explanation: >-
Direct negative result on progression from the largest recent
clinicopathologic follow-up series, explicitly framed against the
morphological-continuum hypothesis.
This report concerns adamantinoma of long bones, not ameloblastoma of the jaw, adamantinomatous craniopharyngioma, or adamantinoma-like Ewing sarcoma (ALES). Those are biologically distinct entities whose similar names commonly produce database-search false positives. Evidence for adamantinoma is limited by extreme rarity; much of the quantitative literature consists of retrospective referral-center series, pathology cohorts, case reports, and narrative reviews rather than prospective trials.
The most useful recent sources retrieved were Węgrzyniak et al., published 30 August 2023 (DOI: 10.12775/JEHS.2023.47.01.003), and Monteiro et al., accepted 9 February 2024. The major primary clinical benchmark remains Keeney et al.’s 85-case series, published 1 August 1989 (DOI: 10.1002/1097-0142(19890801)64:3%3C730::AID-CNCR2820640327%3E3.0.CO;2-P).
| Domain | Evidence-based entry | Suggested ontology |
|---|---|---|
| Definition/classification | Adamantinoma of long bone is a rare primary low-grade malignant bone tumor with biphasic epithelial and osteofibrous components, most often arising in the tibial diaphysis. WHO 2020 places it among “other mesenchymal tumours of bone” and recognizes classic adamantinoma, OFD-like adamantinoma, and dedifferentiated adamantinoma. It is distinct from adamantinoma-like Ewing sarcoma, which is a separate EWSR1/FET-ETS–rearranged round-cell sarcoma mimic rather than true adamantinoma. (wegrzyniak2023currentclinicopathologicalcharacterisation pages 1-5, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9, jain2008adamantinomaaclinicopathological pages 1-2, rekhi2025osteofibrousdysplasia(ofd) pages 8-10) | MONDO: adamantinoma (MONDO_0002422); NCIT: Adamantinoma; MeSH: Adamantinoma; UBERON: tibia, fibula; NCIT/WHO class: other mesenchymal tumours of bone |
| Epidemiology | Reported frequency is ~0.1–0.5% of primary bone tumors. Landmark 85-case series: 70/85 tibial, 11 of those with fibular involvement; age range 3–72 years, average 25.9 years; slight male excess (45 male, 39 female, 1 unknown). Reviews summarize typical presentation at 20–40 years, often 25–35 years. (wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9, keeney1989adamantinomaoflong pages 1-2, jain2008adamantinomaaclinicopathological pages 1-2) | NCIT: Rare Neoplasm; HPO onset terms: Adult onset, Adolescent onset |
| Anatomy/localization | Strong predilection for long bones (reported 97%), especially tibia (80–85%), usually anterior cortex/diaphysis; ipsilateral fibular involvement in ~10–15%. Rare sites include femur, ulna, humerus, radius, ribs, spine, and pretibial soft tissue. Lesions are often intracortical but may extend into medulla and soft tissue. (jain2008adamantinomaaclinicopathological pages 1-2, jain2008adamantinomaaclinicopathological pages 2-4, keeney1989adamantinomaoflong pages 1-2, keeney1989adamantinomaoflong pages 2-3) | UBERON: tibia, fibula, cortical bone, bone marrow, soft tissue; CL: epithelial cell, fibroblast |
| Phenotype/natural history | Presentation is indolent and nonspecific: pain, swelling, stiffness, deformity/bowing, impaired weight-bearing; pathologic fracture reported up to ~23–25%. Course is slow and progressive, with symptoms sometimes present for years before diagnosis; recurrence/metastasis may appear many years later. (jain2008adamantinomaaclinicopathological pages 1-2, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9, keeney1989adamantinomaoflong pages 1-2, kumar2021anunusualcase pages 6-7) | HPO: HP:0012531 Pain; HP:0001382 Joint stiffness; HP:0009826 Limb swelling; HP:0000927 Abnormality of the skeletal system; HP:0002757 Pathological fracture |
| Distinguishing subtypes | Classic adamantinoma: usually >20 years, overt epithelial nests in fibrous stroma, more aggressive malignant behavior. OFD-like adamantinoma: usually younger patients/teens, intracortical lesion with sparse keratin-positive epithelial nests often requiring IHC, better prognosis but long follow-up needed; possible progression to classic tumor reported. Dedifferentiated adamantinoma: classic areas plus high-grade sarcomatous component, more aggressive. Adamantinoma-like Ewing sarcoma differs by molecular fusion status and immunophenotype. (wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9, wegrzyniak2023currentclinicopathologicalcharacterisation pages 9-13, jain2008adamantinomaaclinicopathological pages 2-4, rekhi2025osteofibrousdysplasia(ofd) pages 8-10) | NCIT: Classic Adamantinoma; NCIT: Dedifferentiated Adamantinoma; NCIT/WHO: Osteofibrous dysplasia-like adamantinoma; NCIT: Ewing Sarcoma |
| Molecular findings | Evidence supports epithelial differentiation with cytokeratin expression. Recurrent cytogenetic copy-number abnormalities/gains involving chromosomes 7, 8, 12, 19, and 21 have been reported. Candidate/nonvalidated tumor findings summarized in recent reviews include KMT2D mutation and increased DLK1 expression; these are research-level, not established clinical drivers. Increased epithelial-cell proliferation markers and EGFR expression relative to stromal component have been proposed. No validated germline causal gene, hereditary syndrome, or standard actionable target is established. (wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9, jain2008adamantinomaaclinicopathological pages 6-8, amr2026managementoftibial pages 4-6) | HGNC: KMT2D, DLK1, EGFR, TP53; GO: keratinization/epithelial cell differentiation, cell proliferation; CL: epithelial cell, fibroblast |
| Pathophysiology | Current model is a biphasic neoplasm of epithelial cells embedded in osteofibrous stroma. Reviews propose that the epithelial component is the primary neoplastic population, potentially stimulating stromal proliferation; relation to osteofibrous dysplasia remains debated, with some evidence for a spectrum/continuum in a subset. Mechanistic evidence remains limited and largely histologic/cytogenetic rather than pathway-resolved. (wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9, jain2008adamantinomaaclinicopathological pages 4-5, jain2008adamantinomaaclinicopathological pages 6-8) | GO: epithelial cell proliferation, extracellular matrix organization; CL: epithelial cell, fibroblast; UBERON: cortical bone |
| Diagnosis | Diagnosis integrates radiology, biopsy, histology, and IHC. Radiographs typically show multilocular osteolytic lesion with sclerosis and “soap-bubble” appearance; CT defines cortex and pulmonary metastases; MRI is best for intramedullary, cortical, multifocal, and soft-tissue extent. Histology shows epithelial islands/nests/cords in fibrous stroma with tubular, basaloid, squamous, spindle-cell, or OFD-like patterns. Extensive sampling is important, especially for OFD-like lesions. (jain2008adamantinomaaclinicopathological pages 2-4, wegrzyniak2023currentclinicopathologicalcharacterisation pages 9-13, amr2026managementoftibial pages 4-6, monteiro2024adamantinomadetíbia pages 4-6, jain2008adamantinomaaclinicopathological pages 9-10) | NCIT: Magnetic Resonance Imaging, Computed Tomography, Radiography, Biopsy; HPO: HP:0031837 Osteolytic lesion |
| Diagnostic immunophenotype | Typical tumor epithelial cells are positive for broad cytokeratins, especially CK5/CK14/CK19, and often p63; EMA may be positive in classic lesions but can be variable. IHC is particularly valuable for detecting sparse epithelial nests in OFD-like lesions and excluding mimics. (jain2008adamantinomaaclinicopathological pages 1-2, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9, amr2026managementoftibial pages 4-6, monteiro2024adamantinomadetíbia pages 4-6) | HGNC/Protein markers: KRT5, KRT14, KRT19, TP63, EPCAM/EMA |
| Differential diagnosis | Key differentials: osteofibrous dysplasia, fibrous dysplasia, Ewing sarcoma/adamantinoma-like Ewing sarcoma, osteosarcoma, metastatic carcinoma, vascular tumors, osteomyelitis. OFD is typically strictly intracortical and benign; adamantinoma-like Ewing sarcoma is separated by fusion testing and a different IHC/genetic profile. (jain2008adamantinomaaclinicopathological pages 2-4, jain2008adamantinomaaclinicopathological pages 8-9, wegrzyniak2023currentclinicopathologicalcharacterisation pages 9-13, rekhi2025osteofibrousdysplasia(ofd) pages 8-10) | NCIT: Osteofibrous Dysplasia, Fibrous Dysplasia of Bone, Ewing Sarcoma, Osteosarcoma, Carcinoma Metastatic in Bone |
| Prognosis | Landmark series reported local recurrence in 26/85 (31%), lung metastasis in 13/85 (15%), lymph-node metastasis in 6/85 (7%), and disease-specific death in 11 patients. Reviews summarize recurrence ~18–32% and metastasis ~12–30%, often to lung and regional lymph nodes, with very late events possible. Poorer outcomes are associated with male sex, pain, shorter symptom duration, inadequate/intralesional treatment, and lack of squamous differentiation; margin status is a major predictor. (keeney1989adamantinomaoflong pages 1-2, keeney1989adamantinomaoflong pages 6-7, jain2008adamantinomaaclinicopathological pages 6-8, amr2026managementoftibial pages 6-7, kumar2021anunusualcase pages 6-7) | NCIT: Local Recurrence, Lung Metastasis, Lymph Node Metastasis, Prognostic Factor |
| Treatment/current practice | Standard treatment is wide en-bloc resection with negative margins, usually with limb-salvage reconstruction when feasible. Amputation is reserved for unresectable recurrence, extensive disease, or reconstructive failure. Chemotherapy and radiotherapy have no established routine benefit in conventional adamantinoma. Reconstruction options reported include allograft, vascularized fibular graft, endoprosthetic approaches, and other limb-salvage methods. (jain2008adamantinomaaclinicopathological pages 6-8, kumar2021anunusualcase pages 6-7, amr2026managementoftibial pages 8-9, monteiro2024adamantinomadetíbia pages 4-6) | NCIT: Surgical Resection, Limb Salvage Procedure, Bone Grafting, Amputation |
| Follow-up/prevention | No validated primary-prevention strategy, screening program, or hereditary-risk testing framework is established. Because recurrence and metastasis may occur after long latency, prolonged or lifelong imaging surveillance is recommended after definitive surgery. (keeney1989adamantinomaoflong pages 1-2, amr2026managementoftibial pages 6-7, amr2026managementoftibial pages 8-9) | NCIT: Surveillance, Follow-Up Care |
| Evidence gaps | No robust evidence for infectious cause, environmental cause, protective factors, gene-environment interaction, validated circulating biomarkers, disease-specific staging system, standard targeted therapy, immunotherapy, liquid biopsy, single-cell or spatial transcriptomics atlas, animal model, or natural nonhuman disease counterpart was established in the retrieved evidence. Clinical-trial search did not identify relevant interventional trials for this disease; false-positive hits referred to ameloblastoma/craniopharyngioma. (OpenTargets Search: adamantinoma, wegrzyniak2023currentclinicopathologicalcharacterisation pages 1-5, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9, wegrzyniak2023currentclinicopathologicalcharacterisation pages 9-13) | Evidence gap annotation; NCIT: Not Available / Unknown |
Table: This compact table summarizes the most evidence-supported knowledge-base fields for adamantinoma of long bones, emphasizing distinctions among classic, OFD-like, and adamantinoma-like Ewing entities. It is useful for rapid curation because it combines clinical facts, molecular caveats, and suggested ontology mappings in one place.
Adamantinoma is an exceedingly rare, primary, usually low-grade malignant bone neoplasm characterized by epithelial tumor cells embedded in an osteofibrous or fibroblastic stroma. Its canonical location is the anterior cortex and diaphysis of the tibia. The 2020 WHO classification uses the name “adamantinoma of long bones”, places it among “other mesenchymal tumours of bone,” and recognizes classic, osteofibrous-dysplasia-like (OFD-like), and dedifferentiated forms. OFD-like adamantinoma is classified as intermediate/locally aggressive, whereas classic and dedifferentiated forms are malignant. The 2008 review’s abstract states directly: “Adamantinoma is a primary low-grade, malignant bone tumor that is predominantly located in the mid-portion of the tibia.” (jain2008adamantinomaaclinicopathological pages 1-2, wegrzyniak2023currentclinicopathologicalcharacterisation pages 1-5, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9)
The evidence summarized here is aggregated disease-level literature, not individual EHR-derived data. The 2024 report is an individual clinical case and is identified as such. (monteiro2024adamantinomadetíbia pages 1-4, monteiro2024adamantinomadetíbia pages 4-6)
The cause remains unknown. Epithelial differentiation is strongly supported by broad cytokeratin staining and ultrastructural features including basal lamina and desmosomes. Historical hypotheses—embryonic displacement of basal epidermal cells, traumatic implantation, synovial, vascular, or mesenchymal origin—have not yielded a proven initiating cause. The embryonic-displacement hypothesis was motivated by the tumor’s anterior tibial predilection, where skin lies close to developing bone. (jain2008adamantinomaaclinicopathological pages 1-2)
Presentation is typically insidious, chronic, and progressive. In the 85-case series, among 65 patients with known symptoms, 34 had pain plus swelling, 14 painless swelling, 14 pain alone, and three pathological fracture. Symptom duration ranged from two weeks to 50 years; 41/64 patients had symptoms for less than five years and 23 for at least five years. (keeney1989adamantinomaoflong pages 1-2)
| Phenotype | Type and characteristics | Suggested HPO term |
|---|---|---|
| Localized limb/bone pain | Common symptom; variable severity; chronic progressive course | HP:0012531 Pain; more specific bone-pain term if available |
| Local swelling/mass | Common clinical sign; usually firm, sometimes warm | HP:0009826 Limb swelling |
| Progressive tibial deformity/bowing | Less frequent; reflects anterior cortical remodeling | HP:0000927 Abnormality of the skeletal system; tibial bowing term where supported |
| Pathological fracture | Reported in approximately 10% radiographically in the 85-case study and up to 23% in reviews | HP:0002757 Pathological fracture |
| Stiffness/impaired weight-bearing | Functional manifestation in larger lesions | HP:0001382 Joint stiffness, gait-abnormality term if documented |
| Osteolytic lesion | Imaging phenotype, often multilocular with peripheral sclerosis | HP:0031837 Osteolytic lesion |
| Neurologic deficit | Rare, restricted to spinal disease | Site-specific neurologic HPO term |
| Hypercalcemia | Very rare paraneoplastic finding reported with pulmonary metastases | HP:0003072 Hypercalcemia |
There are no robust disease-specific EQ-5D, SF-36, PROMIS, or utility estimates. Quality of life may be impaired by pain, reduced weight-bearing, deformity, fracture, major resection, graft or prosthetic complications, limb-length discrepancy, repeated reconstruction, or amputation. The 2024 pediatric case explicitly reported limitation of daily activities. (monteiro2024adamantinomadetíbia pages 4-6)
Adamantinoma is not presently a hereditary single-gene disorder. Reported abnormalities are tumor-level/somatic research findings, not clinically validated constitutional pathogenic variants.
The epithelial tumor cells express broad cytokeratins, particularly KRT5, KRT14, and KRT19, and commonly p63; EMA is often reported but may be variable. Older studies found p53 immunoreactivity in epithelial cells. The osteofibrous stroma is vimentin-positive. Keratin expression and epithelial ultrastructure support true epithelial differentiation. (amr2026managementoftibial pages 4-6, jain2008adamantinomaaclinicopathological pages 1-2, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9)
A 2024 classic-tumor case was AE1/AE3-positive in the epithelial component and p63-positive, but EMA, CK19, CD34, and the reported CK99 stain were negative, illustrating that a panel plus morphology is more reliable than any single marker. (monteiro2024adamantinomadetíbia pages 4-6)
No reproducible disease-defining methylation class, histone-mark signature, enhancer alteration, or chromosomal translocation is established for true adamantinoma. This differs critically from ALES, which usually has a FET–ETS fusion such as EWSR1::FLI1. Molecular testing is particularly appropriate in a small-round-cell, head-and-neck, or otherwise atypical “adamantinoma-like” lesion. (rekhi2025osteofibrousdysplasia(ofd) pages 8-10)
No causal toxin, radiation exposure, pollutant, occupational exposure, lifestyle behavior, or infectious agent has been demonstrated. Trauma is best treated as an uncertain historical association rather than an environmental cause. Consequently, there are no evidence-based dietary, exercise, exposure-avoidance, antimicrobial, or vaccination recommendations specific to disease prevention.
The epithelial component has greater Ki-67 and growth-factor/receptor expression than the stroma in older studies, supporting the interpretation that epithelial cells are the neoplastic driver and that osteofibrous tissue is at least partly reactive. Nevertheless, whether OFD, OFD-like adamantinoma, and classic adamantinoma form a universal biological continuum remains disputed. Documented progression supports a continuum in some patients, but older clinicopathologic work did not establish that ordinary OFD is invariably a precursor. (jain2008adamantinomaaclinicopathological pages 4-5, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9)
Suggested annotations include GO epithelial cell proliferation, GO extracellular matrix organization, GO cell population proliferation, and GO epithelial cell differentiation; cell types include CL epithelial cell and CL fibroblast. There is no established disease-specific metabolic, autophagic, immune-checkpoint, inflammatory, mitochondrial, or ion-channel mechanism.
Small genomic/cytogenetic studies exist, but no validated transcriptomic classifier, clinical proteomic or metabolomic signature, lipidomic profile, single-cell atlas, spatial-transcriptomic map, integrated multi-omics cohort, or CRISPR/RNAi dependency screen was identified. These are major research gaps.
Classic adamantinoma most often presents from adolescence through middle adulthood, with a median/typical age around 25–35 years; OFD-like disease is enriched in children and adolescents, generally under 20. The 85-case series had an age range of 3–72 years and mean age 25.9 years. (keeney1989adamantinomaoflong pages 1-2, jain2008adamantinomaaclinicopathological pages 1-2, jain2008adamantinomaaclinicopathological pages 2-4)
The course is chronic and slowly progressive rather than episodic. Local recurrence in the 85-case series occurred after a mean 4.7 years, range 3 months–19.4 years; lymph-node metastasis occurred after a mean 5.8 years, and lung metastasis after a mean 8.2 years, range 1.1–17.9 years. Events several decades after treatment have also been reported, supporting prolonged—often lifelong—surveillance. Spontaneous remission is not expected for classic adamantinoma; apparent regression is discussed principally in OFD/OFD-like lesions. (amr2026managementoftibial pages 6-7, keeney1989adamantinomaoflong pages 3-6)
Adamantinoma is sporadic, with no established autosomal dominant, autosomal recessive, X-linked, mitochondrial, polygenic, or anticipation pattern. Penetrance, carrier frequency, germline mosaicism, founder effects, consanguinity, and prenatal risk are therefore not applicable.
It accounts for approximately 0.1–0.5% of primary bone tumors, but reliable population incidence and point-prevalence estimates per 100,000 are not well established. No consistent ethnic, geographic, or endemic pattern is known. The 85-case cohort included 45 males, 39 females, and one patient of unknown sex; reviews summarize the sex ratio as approximately 5:4 male:female. (keeney1989adamantinomaoflong pages 1-2, jain2008adamantinomaaclinicopathological pages 1-2, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9)
Classic tumors contain bland epithelial nests within fibrous stroma. Patterns include tubular, basaloid, squamous, spindle-cell, and OFD-like forms. Mitoses are usually sparse—historically 0–2 per 10 high-power fields—and marked atypia is unusual outside dedifferentiated disease. OFD-like tumors are predominantly fibro-osseous and may contain only tiny keratin-positive epithelial clusters. (keeney1989adamantinomaoflong pages 2-3, jain2008adamantinomaaclinicopathological pages 2-4, wegrzyniak2023currentclinicopathologicalcharacterisation pages 9-13)
The principal differentials are OFD, fibrous dysplasia, OFD-like adamantinoma, osteosarcoma, Ewing/ALES, intraosseous synovial sarcoma, metastatic carcinoma, epithelioid vascular tumors, nonossifying fibroma, and osteomyelitis. OFD is generally benign and strictly intracortical; true adamantinoma more often extends toward marrow and contains demonstrable epithelial tumor cells. ALES commonly arises in head/neck soft tissue or bone, expresses CD99/NKX2.2 and keratins, and is defined by a FET–ETS fusion. (rekhi2025osteofibrousdysplasia(ofd) pages 8-10, jain2008adamantinomaaclinicopathological pages 2-4, jain2008adamantinomaaclinicopathological pages 8-9)
No diagnostic blood/urine test, circulating biomarker, liquid biopsy, validated WES/WGS panel, CMA, mitochondrial assay, or repeat-expansion test is recommended routinely. There is no population screening or cascade testing.
In the 85-case primary series, 26/85 (31%) developed local recurrence, 13/85 (15%) lung metastases, 6/85 (7%) lymph-node metastases, and 11 died from disease. Nine of 13 patients with lung metastasis had preceding local recurrence, and recurrence significantly increased pulmonary-metastasis risk. (keeney1989adamantinomaoflong pages 1-2, keeney1989adamantinomaoflong pages 3-6, keeney1989adamantinomaoflong pages 6-7)
Broader reviews report local recurrence around 18–32%, metastasis approximately 12–30%, and mortality around 13–18%, but these estimates mix eras and treatments. A modern synthesis cited 5- and 10-year recurrence estimates of 8.6% and 18.6%, 10-year disease-specific survival of 92%, and recurrence-free survival of 72%; interpretation requires caution because source populations and subtype composition differ. (jain2008adamantinomaaclinicopathological pages 6-8, amr2026managementoftibial pages 6-7, amr2026managementoftibial pages 8-9, kumar2021anunusualcase pages 6-7)
Adverse factors reported across retrospective studies include inadequate/intralesional surgery or positive margins, male sex, pain, symptom duration under five years, local recurrence, pathological fracture, skip lesions/periosteal involvement, younger age, and absence of squamous differentiation. Margin status is the most actionable and consistent factor. These associations should not be treated as validated individual-risk calculators. (jain2008adamantinomaaclinicopathological pages 6-8, amr2026managementoftibial pages 8-9, keeney1989adamantinomaoflong pages 1-2, keeney1989adamantinomaoflong pages 6-7)
Wide en-bloc resection with histologically negative margins is the treatment of choice. Limb salvage is preferred when adequate margins and useful function are achievable. Reconstruction may use intercalary allograft, vascularized fibular autograft, bone transport/distraction osteogenesis, endoprosthetic reconstruction, or combinations selected by tumor length, joint involvement, age, and remaining growth. Suggested NCIT terms include Surgical Resection, Wide Excision, Limb Salvage Procedure, Bone Grafting, Reconstructive Surgical Procedure, and Amputation. (jain2008adamantinomaaclinicopathological pages 6-8, amr2026managementoftibial pages 8-9, kumar2021anunusualcase pages 6-7, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9)
Amputation is reserved for unresectable or repeatedly recurrent disease, inability to obtain margins, major neurovascular involvement, infection, or failed reconstruction; it has not shown an inherent survival advantage over adequate wide resection. Curettage and other intralesional procedures are inappropriate for classic adamantinoma because of high recurrence risk. (amr2026managementoftibial pages 6-7, wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9)
Conventional chemotherapy and radiotherapy have no established routine efficacy. Anecdotal use of tyrosine-kinase inhibitors such as pazopanib or sunitinib has been discussed for unresectable/metastatic disease, but there is no validated response rate, approved adamantinoma-specific target, or standard regimen. Genotype-guided therapy, checkpoint inhibition, CAR-T therapy, gene therapy, ASOs/siRNA, and mRNA therapy are investigational or unsupported. (jain2008adamantinomaaclinicopathological pages 6-8, amr2026managementoftibial pages 8-9, kumar2021anunusualcase pages 6-7)
A ClinicalTrials.gov search did not identify a relevant adamantinoma interventional study; retrieved hits concerned similarly named ameloblastoma or craniopharyngioma and must not be assigned to this disease.
Management includes analgesia, fracture precautions, physical and occupational therapy, gait training, orthotics/prosthetics when appropriate, surveillance of graft union and hardware, and psychosocial support. Reconstruction can require repeated revision because of nonunion, graft fracture, infection, limb-length discrepancy, or prosthetic failure. No adamantinoma-specific pharmacogenomic guidance exists.
There is no known primary prevention because no modifiable cause is established. There is no population, newborn, carrier, prenatal, or germline screening program and no vaccine or prophylactic drug.
Secondary prevention consists of prompt specialist assessment of persistent tibial pain, swelling, deformity, or a characteristic cortical lesion and avoiding unplanned curettage. Tertiary prevention includes complete initial resection, fracture prevention, rehabilitation, and very long-term local and chest surveillance. Genetic counseling is not routinely indicated for familial risk, although counseling about the absence of demonstrated heritability may be useful.
No well-validated naturally occurring veterinary counterpart, breed predisposition, orthologous causal gene, cross-species susceptibility, or comparative spontaneous-disease cohort was identified. Adamantinoma is not infectious and has no zoonotic or cross-species transmission potential. Reports using “adamantinoma” in veterinary or older pathology sources require careful review because the term has historically been applied to odontogenic tumors.
No standardized mouse, rat, zebrafish, invertebrate, genetically engineered, humanized, patient-derived xenograft, organoid, iPSC, or validated cell-line model was identified. Consequently, no model has been shown to reproduce the human tibial cortical localization, biphasic epithelial–osteofibrous architecture, prolonged latency, or late metastatic behavior. Development of authenticated patient-derived cultures, organoids, xenografts, and spatial/single-cell datasets is a major unmet research need.
The 2023 review emphasizes three practical developments: adoption of the 2020 WHO three-part classification, increasing use of combined immunohistochemical and genetic assessment, and MRI-based definition of full tumor extent before wide-margin surgery. Its abstract concludes that “confirmation of the immunohistochemical profile, as well as the genetic profile…is essential for diagnosis” and that the best treatment remains resection with large margins. (wegrzyniak2023currentclinicopathologicalcharacterisation pages 1-5)
The 2024 tibial case illustrates current real-world implementation: serial radiography, CT and MRI; centrally sampled biopsy; morphology plus p63/AE1-AE3 IHC; and limb-preserving resection/reconstruction. It also demonstrates the risk of misleading early imaging labels and postoperative functional complications in young patients. (monteiro2024adamantinomadetíbia pages 1-4, monteiro2024adamantinomadetíbia pages 4-6)
The central expert conclusion is that adamantinoma remains a surgically curable but deceptively persistent malignancy. Accurate subtype assignment, exclusion of molecular mimics, complete initial resection, and decades-long surveillance are more clinically consequential than presently available molecular-targeting strategies.
References
(wegrzyniak2023currentclinicopathologicalcharacterisation pages 1-5): A Węgrzyniak, W Wokurka, and D Drobek. Current clinicopathological characterisation of adamantinoma-a review of the literature. Unknown journal, 2023.
(wegrzyniak2023currentclinicopathologicalcharacterisation pages 5-9): A Węgrzyniak, W Wokurka, and D Drobek. Current clinicopathological characterisation of adamantinoma-a review of the literature. Unknown journal, 2023.
(jain2008adamantinomaaclinicopathological pages 1-2): Deepali Jain, Vijay K Jain, Rakesh K Vasishta, Prabhat Ranjan, and Yashwant Kumar. Adamantinoma: a clinicopathological review and update. Diagnostic Pathology, 3:8-8, Feb 2008. URL: https://doi.org/10.1186/1746-1596-3-8, doi:10.1186/1746-1596-3-8. This article has 130 citations and is from a peer-reviewed journal.
(rekhi2025osteofibrousdysplasia(ofd) pages 8-10): B Rekhi, R Jayan, R Jayan, and B Rekhi. Osteofibrous dysplasia (ofd) and adamantinoma: a comprehensive review and updates. Histology and histopathology, pages 18950, Jun 2025. URL: https://doi.org/10.14670/hh-18-950, doi:10.14670/hh-18-950. This article has 3 citations and is from a peer-reviewed journal.
(keeney1989adamantinomaoflong pages 1-2): Gary L. Keeney, K. Krishnan Unni, John W. Beabout, and Douglas J. Pritchard. Adamantinoma of long bones. a clinicopathologic study of 85 cases. Cancer, 64:730-737, Aug 1989. URL: https://doi.org/10.1002/1097-0142(19890801)64:3<730::aid-cncr2820640327>3.0.co;2-p, doi:10.1002/1097-0142(19890801)64:3<730::aid-cncr2820640327>3.0.co;2-p. This article has 218 citations and is from a domain leading peer-reviewed journal.
(jain2008adamantinomaaclinicopathological pages 2-4): Deepali Jain, Vijay K Jain, Rakesh K Vasishta, Prabhat Ranjan, and Yashwant Kumar. Adamantinoma: a clinicopathological review and update. Diagnostic Pathology, 3:8-8, Feb 2008. URL: https://doi.org/10.1186/1746-1596-3-8, doi:10.1186/1746-1596-3-8. This article has 130 citations and is from a peer-reviewed journal.
(keeney1989adamantinomaoflong pages 2-3): Gary L. Keeney, K. Krishnan Unni, John W. Beabout, and Douglas J. Pritchard. Adamantinoma of long bones. a clinicopathologic study of 85 cases. Cancer, 64:730-737, Aug 1989. URL: https://doi.org/10.1002/1097-0142(19890801)64:3<730::aid-cncr2820640327>3.0.co;2-p, doi:10.1002/1097-0142(19890801)64:3<730::aid-cncr2820640327>3.0.co;2-p. This article has 218 citations and is from a domain leading peer-reviewed journal.
(kumar2021anunusualcase pages 6-7): Arvind Kumar, Ruchi Sharma, Anil Kumar Verma, Abhijeet Tiwari, and Jyoti Mishra. An unusual case of adamantinoma of long bone. Autopsy & Case Reports, 11:e2021276, May 2021. URL: https://doi.org/10.4322/acr.2021.276, doi:10.4322/acr.2021.276. This article has 7 citations.
(wegrzyniak2023currentclinicopathologicalcharacterisation pages 9-13): A Węgrzyniak, W Wokurka, and D Drobek. Current clinicopathological characterisation of adamantinoma-a review of the literature. Unknown journal, 2023.
(jain2008adamantinomaaclinicopathological pages 6-8): Deepali Jain, Vijay K Jain, Rakesh K Vasishta, Prabhat Ranjan, and Yashwant Kumar. Adamantinoma: a clinicopathological review and update. Diagnostic Pathology, 3:8-8, Feb 2008. URL: https://doi.org/10.1186/1746-1596-3-8, doi:10.1186/1746-1596-3-8. This article has 130 citations and is from a peer-reviewed journal.
(amr2026managementoftibial pages 4-6): Yasser Amr, Aye Htun, and Simerjit Singh. Management of tibial adamantinoma: balancing oncologic cure and reconstructive longevity. Cureus, Aug 2026. URL: https://doi.org/10.7759/cureus.113794, doi:10.7759/cureus.113794. This article has 0 citations.
(jain2008adamantinomaaclinicopathological pages 4-5): Deepali Jain, Vijay K Jain, Rakesh K Vasishta, Prabhat Ranjan, and Yashwant Kumar. Adamantinoma: a clinicopathological review and update. Diagnostic Pathology, 3:8-8, Feb 2008. URL: https://doi.org/10.1186/1746-1596-3-8, doi:10.1186/1746-1596-3-8. This article has 130 citations and is from a peer-reviewed journal.
(monteiro2024adamantinomadetíbia pages 4-6): LS de Sousa Monteiro and LF Vitule. Adamantinoma de tíbia: adamantinoma of the tibia. Unknown journal, 2024.
(jain2008adamantinomaaclinicopathological pages 9-10): Deepali Jain, Vijay K Jain, Rakesh K Vasishta, Prabhat Ranjan, and Yashwant Kumar. Adamantinoma: a clinicopathological review and update. Diagnostic Pathology, 3:8-8, Feb 2008. URL: https://doi.org/10.1186/1746-1596-3-8, doi:10.1186/1746-1596-3-8. This article has 130 citations and is from a peer-reviewed journal.
(jain2008adamantinomaaclinicopathological pages 8-9): Deepali Jain, Vijay K Jain, Rakesh K Vasishta, Prabhat Ranjan, and Yashwant Kumar. Adamantinoma: a clinicopathological review and update. Diagnostic Pathology, 3:8-8, Feb 2008. URL: https://doi.org/10.1186/1746-1596-3-8, doi:10.1186/1746-1596-3-8. This article has 130 citations and is from a peer-reviewed journal.
(keeney1989adamantinomaoflong pages 6-7): Gary L. Keeney, K. Krishnan Unni, John W. Beabout, and Douglas J. Pritchard. Adamantinoma of long bones. a clinicopathologic study of 85 cases. Cancer, 64:730-737, Aug 1989. URL: https://doi.org/10.1002/1097-0142(19890801)64:3<730::aid-cncr2820640327>3.0.co;2-p, doi:10.1002/1097-0142(19890801)64:3<730::aid-cncr2820640327>3.0.co;2-p. This article has 218 citations and is from a domain leading peer-reviewed journal.
(amr2026managementoftibial pages 6-7): Yasser Amr, Aye Htun, and Simerjit Singh. Management of tibial adamantinoma: balancing oncologic cure and reconstructive longevity. Cureus, Aug 2026. URL: https://doi.org/10.7759/cureus.113794, doi:10.7759/cureus.113794. This article has 0 citations.
(amr2026managementoftibial pages 8-9): Yasser Amr, Aye Htun, and Simerjit Singh. Management of tibial adamantinoma: balancing oncologic cure and reconstructive longevity. Cureus, Aug 2026. URL: https://doi.org/10.7759/cureus.113794, doi:10.7759/cureus.113794. This article has 0 citations.
(OpenTargets Search: adamantinoma): Open Targets Query (adamantinoma, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(monteiro2024adamantinomadetíbia pages 1-4): LS de Sousa Monteiro and LF Vitule. Adamantinoma de tíbia: adamantinoma of the tibia. Unknown journal, 2024.
(keeney1989adamantinomaoflong pages 3-6): Gary L. Keeney, K. Krishnan Unni, John W. Beabout, and Douglas J. Pritchard. Adamantinoma of long bones. a clinicopathologic study of 85 cases. Cancer, 64:730-737, Aug 1989. URL: https://doi.org/10.1002/1097-0142(19890801)64:3<730::aid-cncr2820640327>3.0.co;2-p, doi:10.1002/1097-0142(19890801)64:3<730::aid-cncr2820640327>3.0.co;2-p. This article has 218 citations and is from a domain leading peer-reviewed journal.
Checked with linkml-reference-validator 0.2.1.
| Outcome | Count |
|---|---|
| References checked | 8 |
| Resolved | 5 |
| Unresolved (possible confabulation) | 1 |
| Unverifiable | 2 |
| References weighed for topical relevance | 5 |
| On topic | 1 |
| Off topic | 0 |
These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:
DOI:10.14670/hh-18-950 (3 mentions) - Identifier did not resolve to a record